11Dec 2023
Tislelizumab Shows Promising Safety and Efficacy in Treating Non-Small Cell Lung Cancer

Tislelizumab Shows Promising Safety and Efficacy in Treating Non-Small Cell Lung Cancer

A comprehensive review assessed the safety and efficacy of Tislelizumab, an anti-PD-1 monoclonal antibody, in treating non-small cell lung cancer (NSCLC). The study examined four randomized controlled trials with 1565 patients and found that Tislelizumab significantly improved progression-free survival and objective response rate, especially in combination with chemotherapy. However, both treatment arms reported treatment-emergent adverse events, with hematologic issues being prominent. The study concludes that Tislelizumab exhibits both safety and efficacy as a potential NSCLC treatment, warranting further exploration.

  • #pulmonology

Like

Save

Share